Video

Dr. Paulson Discusses Acquired Resistance to Immunotherapy

Author(s):

Kelly Paulson, MD
Conference|SITC Meeting

Kelly Paulson, MD, fellow, Seattle Cancer Care Alliance, discusses acquired resistance to immunotherapy during The Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting.

Kelly Paulson, MD, fellow, Seattle Cancer Care Alliance, discusses acquired resistance to immunotherapy during The Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting.

One of the biggest challenges in immunotherapy is resistance to treatment, says Paulson. Investigators are currently trying to develop next-generation immunotherapies to treat patients who initially responded to immunotherapy, but then recurred.

Related Videos
Erminia Massarelli, MD, PhD, MS
Karen L. Reckamp, MD, MS
Jacob Sands, MD, oncology medical director, International Patient Center, Dana-Farber Cancer Institute; assistant professor, Harvard Medical School
Fred R. Hirsch, MD, PhD, executive director, Center for Thoracic Oncology, The Tisch Cancer Institute at Mount Sinai; Joe Lowe and Louis Price Professor of Medicine (Hematology and Medical Oncology), Icahn School of Medicine at Mount Sinai
Lori Wirth, MD
Tanios Bekaii-Saab, MD, FACP
Moritz Fürstenau, MD
Jun Gong, MD
Thierry Facon, MD
Alicia Morgans, MD, MPH, genitourinary medical oncologist, medical director, Survivorship Program, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Related Content
Eliav Barr, MD, of Merck Research Laboratories
July 26th 2024

Pembrolizumab Plus Enfortumab Vedotin Earns CHMP Recommendation in Frontline Metastatic Urothelial Carcinoma

Marvels in Medicine: Allison Talks Everything from Advances in Immunotherapy to Jamming With Willie Nelson
November 22nd 2021

Marvels in Medicine: Allison Talks Everything from Advances in Immunotherapy to Jamming With Willie Nelson

Suthee Rapisuwon, MD
July 16th 2024

Adjuvant Nivolumab/Ipilimumab Lengthens DMFS in High-Risk Uveal Melanoma

Dietrich Details Data and Future Research With Immunotherapy in Stage III NSCLC
September 20th 2021

Dietrich Details Data and Future Research With Immunotherapy in Stage III NSCLC

Robert Metcalf, MBChB, MRCP, PhD, of Christie National Health Service Foundation Trust
July 11th 2024

First-line Eftilagimod Alpha Plus Pembrolizumab Generates Favorable ORR in PD-L1–Negative HNSCC

Don Dizon, MD, of Lifespan Cancer Institute
July 10th 2024

Nivolumab/Ipilimumab Yields Responses in Ovarian Clear Cell Carcinoma